$5.86
−2.50%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$5.98
From 52W high−32.25%
Volume96922.00
Market cap$214.13M
P/E (TTM)—
P/S (TTM)11.3x
Div yield—
Key dataOct 19, 2026
Open
$5.98
From 52W high
−32.25%
Volume
96922.00
Market cap
$214.13M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.5x
P/E (TTM)
—
RSI (14)
43.9
MomentumView details →
1D Return
−2.50%
YTD Return
−24.69%
SummaryUpdated Jun 1, 2026
Profound Medical Corp. (NASDAQ:PROF) is a Canadian commercial-stage medical device company founded in 2008 and headquartered in Mississauga, Ontario. The company went public on NASDAQ in October 2019, following earlier listings on the Toronto Stock Exchange. Profound Medical specializes in developing and commercializing magnetic resonance-guided ablation procedures for treating various medical conditions, with its primary focus on prostate diseases, uterine fibroids, and palliative pain treatment. The company operates primarily in Canada, the United States, Germany, and Finland, representing a specialized player in the emerging field of MR-guided focused ultrasound therapy.
Similar companies
Latest newsMore news →
Profound Medical announced that five abstracts presented at the Profound Medical Corp. support the real-world performance, clinical differentiation and platform expansion potential of its TULSA Procedure using the TULSA-PRO system.6d agoProfound Medical Corp. shares rose 21.7% in the last trading session on above-average volume.11d agoProfound Medical Corp. announced preliminary third-quarter 2026 revenue of $9.8 million to $10.0 million, approximately 45% to 47% above Bloomberg LP analyst consensus.12d ago